Strong preclinical data on FG001’s potential in guiding surgical removal of pancreatic cancer has been accepted for presentation on the World Molecular Imaging Congress 2019
FluoGuide A/S’s ("FluoGuide") compound FG001 lights up the cancer and has demonstrated potential to vastly improve the radicality of surgery in preclinical studies. FG001 use is initially focused on glioblastoma, but FluoGuide is pleased to announce that data, confirming FG001’s potential in also guiding surgical removal of pancreatic cancer, will be presented at the World Molecular Imaging Congress 2019 (WMIC) in Montreal, on 4-7 September 2019.FG001 is initially focused on guiding glioblastoma surgery but has potential in several other cancer indications. One of these indications is